Citizens raises Taysha price target to $11, maintains outperform
Citizens analyst Silvan Tuerkcan maintained a Market Outperform rating on Taysha Gene Therapies and increased the price target from $8 to $11.
*this image is generated using AI for illustrative purposes only.
Citizens analyst Silvan Tuerkcan has maintained a Market Outperform rating on Taysha Gene Therapies and raised the price target to $11. The previous target was $8. The company trades on the NASDAQ under the ticker symbol TSHA.
Rating and Target Details
The revised price target reflects an increased valuation outlook for the biotechnology firm. The Market Outperform rating indicates expectations for the stock to perform better than the broader market average.
| Metric | Value |
|---|---|
| Rating | Market Outperform |
| New Price Target | $11 |
| Previous Price Target | $8 |
What specific factors drove the 37.5% increase in Taysha's price target?
How might this rating upgrade influence investor sentiment towards Taysha in the short term?
What upcoming clinical milestones could further impact Taysha's stock performance?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
